Aventis Extends License for Genome Therapeutics' Microbial Database

Apr 03, 2001, 01:00 ET from Genome Therapeutics Corp.

    WALTHAM, Mass., April 3 /PRNewswire/ --Genome Therapeutics Corp.
 (Nasdaq:   GENE) today announced that Aventis Pharma S.A. has renewed its
 license for access to Genome Therapeutics' proprietary PathoGenome(TM)
 Database, a key component of the Company's genomics services business. Aventis
 researchers will continue to utilize the PathoGenome(TM) Database to aid in
 the discovery of novel classes of anti-infectives.
    "The PathoGenome(TM) Database has proven a robust source of targets to fuel
 our discovery efforts for novel anti-infectives products," said Francois
 Meyer, Senior Vice President, Head of Drug Innovation and Approval, Aventis
 France. "We are very pleased to extend this productive relationship with
 Genome Therapeutics."
     Under terms of the agreement, Aventis will continue to have non-exclusive
 access to the information contained in Genome Therapeutics' PathoGenome(TM)
 Database, extending a subscription originally obtained in 1998. In return,
 Aventis will pay annual subscription fees and royalties on any small molecules
 developed as a result of the collaboration. Genome Therapeutics retains rights
 associated with the therapeutic and vaccine use of bacterial genes or gene
 products derived from the PathoGenome(TM) Database. No other terms were
 disclosed.
     "Aventis has had extensive success with the PathoGenome(TM) Database in
 defining key molecular targets in pathogenic micro-organisms for the
 development of new medicines," said Steven M. Rauscher, CEO and President of
 Genome Therapeutics. "By renewing its contract, Aventis validates the power
 and importance of our proprietary sequence information in their drug discovery
 efforts."
     The PathoGenome(TM) Database provides customers with a large volume of
 highly organized and functionally annotated sequence information about more
 than 30 microbial pathogens, including Staphylococcus, Pseudomonas,
 Streptococcus, Enterococcus, Acinetobacter, Aspergillus, Bacteroides,
 Enterobacter, Klebsiella, and Candida species. Launched in 1997, this database
 was originally available only by subscription. In addition to Aventis, other
 subscribers include Bayer, bioMerieux, Bristol-Myers Squibb and Schering-
 Plough. The PathoGenome(TM) Database is also available on a pay-per-use basis
 at Compugen's search engine LabOnWeb.com.
 
     Genome Therapeutics (www.genomecorp.com) is focused on the
 commercialization of genomics-based pharmaceutical, vaccine and diagnostic
 products. The Company operates two lines of business: genomics services and
 biopharmaceuticals. The services business focuses on genomics-based drug
 discovery services that enable other organizations to achieve their research
 objectives and includes the GTC Sequencing Center and the PathoGenome(TM)
 Database. The biopharmaceutical business focuses on the development of novel
 therapeutics, vaccines and diagnostics to solve major medical needs and
 includes six alliances with pharmaceutical companies including Schering-
 Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux, with research initiatives to
 develop genomics-based products.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements as defined in the Private Securities Litigation
 Reform Act of 1995. A number of important factors could cause actual results
 to differ materially from those projected or suggested in the forward looking
 statement, including, but not limited to, the ability of the Company and its
 alliance partners to (i) successfully develop products based on the Company's
 genomic information, (ii) obtain the necessary governmental approvals, (iii)
 effectively commercialize any products developed before its competitors and
 (iv) obtain and enforce intellectual property rights, as well as the risk
 factors described in Exhibit 99 of the Company's Annual Report on Form 10-K
 for the fiscal year ended August 31, 2000 and from time to time in the
 Company's other reports filed with the Securities and Exchange Commission.
 
 

SOURCE Genome Therapeutics Corp.
    WALTHAM, Mass., April 3 /PRNewswire/ --Genome Therapeutics Corp.
 (Nasdaq:   GENE) today announced that Aventis Pharma S.A. has renewed its
 license for access to Genome Therapeutics' proprietary PathoGenome(TM)
 Database, a key component of the Company's genomics services business. Aventis
 researchers will continue to utilize the PathoGenome(TM) Database to aid in
 the discovery of novel classes of anti-infectives.
    "The PathoGenome(TM) Database has proven a robust source of targets to fuel
 our discovery efforts for novel anti-infectives products," said Francois
 Meyer, Senior Vice President, Head of Drug Innovation and Approval, Aventis
 France. "We are very pleased to extend this productive relationship with
 Genome Therapeutics."
     Under terms of the agreement, Aventis will continue to have non-exclusive
 access to the information contained in Genome Therapeutics' PathoGenome(TM)
 Database, extending a subscription originally obtained in 1998. In return,
 Aventis will pay annual subscription fees and royalties on any small molecules
 developed as a result of the collaboration. Genome Therapeutics retains rights
 associated with the therapeutic and vaccine use of bacterial genes or gene
 products derived from the PathoGenome(TM) Database. No other terms were
 disclosed.
     "Aventis has had extensive success with the PathoGenome(TM) Database in
 defining key molecular targets in pathogenic micro-organisms for the
 development of new medicines," said Steven M. Rauscher, CEO and President of
 Genome Therapeutics. "By renewing its contract, Aventis validates the power
 and importance of our proprietary sequence information in their drug discovery
 efforts."
     The PathoGenome(TM) Database provides customers with a large volume of
 highly organized and functionally annotated sequence information about more
 than 30 microbial pathogens, including Staphylococcus, Pseudomonas,
 Streptococcus, Enterococcus, Acinetobacter, Aspergillus, Bacteroides,
 Enterobacter, Klebsiella, and Candida species. Launched in 1997, this database
 was originally available only by subscription. In addition to Aventis, other
 subscribers include Bayer, bioMerieux, Bristol-Myers Squibb and Schering-
 Plough. The PathoGenome(TM) Database is also available on a pay-per-use basis
 at Compugen's search engine LabOnWeb.com.
 
     Genome Therapeutics (www.genomecorp.com) is focused on the
 commercialization of genomics-based pharmaceutical, vaccine and diagnostic
 products. The Company operates two lines of business: genomics services and
 biopharmaceuticals. The services business focuses on genomics-based drug
 discovery services that enable other organizations to achieve their research
 objectives and includes the GTC Sequencing Center and the PathoGenome(TM)
 Database. The biopharmaceutical business focuses on the development of novel
 therapeutics, vaccines and diagnostics to solve major medical needs and
 includes six alliances with pharmaceutical companies including Schering-
 Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux, with research initiatives to
 develop genomics-based products.
 
     Statements in this press release that are not strictly historical are
 "forward looking" statements as defined in the Private Securities Litigation
 Reform Act of 1995. A number of important factors could cause actual results
 to differ materially from those projected or suggested in the forward looking
 statement, including, but not limited to, the ability of the Company and its
 alliance partners to (i) successfully develop products based on the Company's
 genomic information, (ii) obtain the necessary governmental approvals, (iii)
 effectively commercialize any products developed before its competitors and
 (iv) obtain and enforce intellectual property rights, as well as the risk
 factors described in Exhibit 99 of the Company's Annual Report on Form 10-K
 for the fiscal year ended August 31, 2000 and from time to time in the
 Company's other reports filed with the Securities and Exchange Commission.
 
 SOURCE  Genome Therapeutics Corp.